ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

MediLink Therapeutics (Suzhou) and BioNTech side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

MediLink Therapeutics (Suzhou)BioNTech
studies on the registry23124
open to participants now1832
phase 3 studies under way79
reach primary completion within a year911
programswith a study of their own in two years523

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMediLink Therapeutics (Suzhou)BioNTech
Phase 1

MediLink Therapeutics (Suzhou): 1 of its 5 programs at phase 1

  1. Anti-CDH17 Antibody-drug Conjugate YL217phase 1
20%

BioNTech: 4 of its 23 programs at phase 1

  1. BNT168phase 1
  2. BNT3219phase 1
  3. BNT351phase 1
  4. CV09070101phase 1
17%
Phase 2

MediLink Therapeutics (Suzhou): 2 of its 5 programs at phase 2

  1. aflutinibphase 2
  2. Anti-VEGF Antibody-drug Conjugate YL242phase 2
40%
65%
Phase 3

MediLink Therapeutics (Suzhou): 2 of its 5 programs at phase 3

  1. tambotatug pelitecanphase 3
  2. beruzatatug pelitecanphase 3
40%

BioNTech: 3 of its 23 programs at phase 3

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3
  3. trastuzumab pamirtecanphase 3
13%
Approved, new studies00%

BioNTech: 1 of its 23 programs at approved, new studies

  1. BNT162 Vaccineapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
MediLink Therapeutics (Suzhou)2 readouts · 0 phase 3

MediLink Therapeutics (Suzhou), Nov ’26: 1 program whose next study reaches primary completion

  1. beruzatatug pelitecanphase 3 · Nov 0 · NCT06107686
·

MediLink Therapeutics (Suzhou), Jan ’27: 1 program whose next study reaches primary completion

  1. tambotatug pelitecanphase 3 · Jan 0 · NCT07208773
·········
BioNTech4 readouts · 1 phase 3

BioNTech, Nov ’26: 1 program whose next study reaches primary completion

  1. BNT351phase 1 · Nov 0 · NCT07392372
·

BioNTech, Jan ’27: 1 program whose next study reaches primary completion

  1. pumitamigphase 3 · Jan 1 · NCT05879055
··

BioNTech, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. BNT162 Vaccineapproved, new study · Apr 12 · NCT07798648
·

BioNTech, Jun ’27: 1 program whose next study reaches primary completion

  1. BNT166Aphase 2 · Jun 0 · NCT07379580
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

MediLink Therapeutics (Suzhou)

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

BioNTech

New programs 2

  • BNT3219phase 1 · first study · Oct 19
  • BNT3210phase 2 · first study · Oct 15

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionMediLink Therapeutics (Suzhou)BioNTech
Breast Neoplasmsboth · compare here

MediLink Therapeutics (Suzhou) in Breast Neoplasms: 2 programs

  1. beruzatatug pelitecanphase 3
  2. aflutinibphase 2

Their studies: MediLink Therapeutics (Suzhou)’s studies of Breast Neoplasms in search

BioNTech in Breast Neoplasms: 3 programs

  1. pumitamigphase 3
  2. trastuzumab pamirtecanphase 3
  3. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Breast Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

MediLink Therapeutics (Suzhou) in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. tambotatug pelitecanphase 3
  2. beruzatatug pelitecanphase 3
  3. aflutinibphase 2

Their studies: MediLink Therapeutics (Suzhou)’s studies of Carcinoma, Non-Small-Cell Lung in search

BioNTech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. pumitamigphase 3
  2. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Carcinoma, Non-Small-Cell Lung in search

Small Cell Lung Carcinomaboth · compare here

MediLink Therapeutics (Suzhou) in Small Cell Lung Carcinoma: 1 program

  1. tambotatug pelitecanphase 3

Their studies: MediLink Therapeutics (Suzhou)’s studies of Small Cell Lung Carcinoma in search

BioNTech in Small Cell Lung Carcinoma: 2 programs

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3

Their studies: BioNTech’s studies of Small Cell Lung Carcinoma in search

Melanomaboth · compare here

MediLink Therapeutics (Suzhou) in Melanoma: 1 program

  1. beruzatatug pelitecanphase 3

Their studies: MediLink Therapeutics (Suzhou)’s studies of Melanoma in search

BioNTech in Melanoma: 1 program

  1. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Melanoma in search

Neoplasm Metastasisboth · compare here

MediLink Therapeutics (Suzhou) in Neoplasm Metastasis: 1 program

  1. aflutinibphase 2

Their studies: MediLink Therapeutics (Suzhou)’s studies of Neoplasm Metastasis in search

BioNTech in Neoplasm Metastasis: 1 program

  1. trastuzumab pamirtecanphase 3

Their studies: BioNTech’s studies of Neoplasm Metastasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: MediLink Therapeutics (Suzhou) 5 of 5 · BioNTech 11 of 23 programs (10 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.